Movano Health

This is a pro forma financial disclosure documenting Movano Inc.'s March 19, 2026 acquisition of Corvex Legacy Holdings, Inc., with Movano rebranding as Corvex, Inc. The filing presents unaudited pro forma combined statements as if the merger had closed January 1, 2025. For H1 2026, pro forma revenue totaled $4.3 million with a net loss of $26.2 million. For full-year 2025, pro forma revenue was $7.5 million with a net loss of $67.5 million. The merger consideration comprised 240.6 shares of Series B Preferred Stock (converted to 240.5K common shares), 23.6M Series C Preferred shares (converted post-stockholder approval in July 2026), and 30.2M Series D Preferred shares (convertible at holder option). The company recorded $519.3 million in goodwill and $15.4 million in identifiable intangible assets. No forward guidance was provided in this acquisition-accounting document. The disclosure emphasizes preliminary valuations subject to change within the 12-month measurement period.

No articles ingested yet for Movano Health. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.